Biocompatibility Hub
  • Home
  • Suppliers
    • Contract Laboratories >
      • Toxikon
      • Nelson Labs
      • Eurofins
    • Material Suppliers
    • Contract Manufacturers
    • Consultants >
      • Intrinsic Medical Group
  • Library
    • Which Endpoints Should I Consider?
    • Test Method Summaries
    • White Papers, Articles and Presentations >
      • FDA Guidance: Coronary, Peripheral, and Neurovascular Guidewires
      • FDA Recognized Consensus Standards Update
      • The Ten Steps of a Biological Evaluation whtin a Risk Management Process
      • Post-Approval Biocompatibility
      • The Failed Cytotoxicity Test
      • Biocompatibility Deficiency Letters Part 2
      • ISO 18562-1 (2017) Biocompatibility Evaluation of Breathing Gas Pathways
      • In-Vivo Thrombogenicity 101
      • Technical Considerations for Additive Manufactured (3D Printed) Devices
      • How to Pick a Biocompatibility CRO
      • Mitigating Risk in Biocompatibility
      • Biocompatibility Deficiency Letters
      • The First Steps in Biocompatibility
  • Contact
    • About
  • Search

ISO 10993-6 2016
​Implantation

The Basic Study design requirements
Definitions
Absorb/Absorption is defined as being assimilated by cells or tissue over time.
Degradation is defined as the decomposition of a material.
A degradation product is the product of a material which is generated by the physical, metabolic, and/or chemical breakdown or decomposition of the material.
A Biomaterial is a material intended to interface with biological systems to evaluate, treat, augment or replace any tissue, organ or function of the body.

The control should have physical characteristics as similar as possible.

The implant shall be manufactured, processed, cleaned and sterilized as for the finished product.  Should be handled in a manner to protect the integrity of the prepared finished product.  Sample preparation should be as described in ISO 10993-12.

It may be appropriate that products that are scaffolds and biologics to test the scaffold without the tissue engineered component due to immune responses.

Products that cure in situ should be tested in a manner that the polymerizing occurs in situ.

Non-Solid test articles may be put into tubes.

The site of implantation should be clinically relevant.

Absorbable material implants sites should be marked with non-absorbable material such as negative control, pp suture, gold bands or clips.

Short term testing is commonly done in rodents or rabbits and long term testing is commonly done in rodents, rabbits, dogs, sheep, goats, and pigs.

The in vitro degradation should be considered first and a preliminary study done in rodents before testing in a larger animal.

Test and control should be in the same animal, but if evaluated as part of a toxicity study, or a neuroimplantation test and control should not be in the same animal.

Inert materials are tested at a short timepoint of 1 to 4 weeks and long timepoints exceeding 12 weeks.  A steady state of biological response should be the goal.  Time points of bone implantations are longer than soft tissue.

Timepoints should go beyond absorption for degradable and absorbable test articles.  
At least three time points for absorbable materials.  Before, during and after.   This may require building additional animals and timepoints for materials with long absorption profiles.

Pre-degraded materials may be acceptable on a case by case basis.

It is recommended to get implant data from tox studies dosed by implantation.

Macroscopic evaluation of regional lymph nodes should be conducted.  The sites should be evaluated macroscopically for hematoma, edema, encapsulation and any other abnormal findings.  This can occur after tissue fixation.

Microscopic evaluation should assess inflammation, neovascularization, fibrosis, fatty infiltrate, and necrosis on a scale of 0 to 4 running from none to packed, extensive or severe.  The scores for each site is tallied, eventually all the numbers are crunched to have an overall mean score for all sites for all animals for both test and controls.  The control score is subtracted from the test for the overall score.  The test article is then classified as a non, slight, moderate or severe irritant based upon the scores which can range from 0 to over 15.

Subcutaneous implantation

    Sizes for various types of test articles are suggested.  The common measurement is a thickness of of approximately 1.5 mm.  .

Other sizes appropriate when doing a tox study by implantation.

A non-absorbable control is needed at each timepoint

In the subcutaneous space of rats, mice, guinea pigs, or rabbits

A minimum of 3 animals and a minimum of 10 sites of each material.

Anatomical sites suggested of along the dorsal midline, or in the neck.

Intramuscular Implantation

The implant should be 1 to 3 mm in diameter and 10 mm long with rounded ends.

The paravertebral muscles of rabbits are the preferred site.

A minimum of 3 animals to yield a minimum of 10 test and 10 control sites.

A non-absorbable control at each timepoint

Implantation using a hypodermic needle is specified although alternative methods can be used when appropriate for the test article.  Larger implants can be put in surgically.

Implantation into bone

The implant can be screw shaped to add stability to the implant.  Also a cylinder is acceptable. And will be 2 mm in diameter and 6 mm in length if cylinders used in rabbits, 4 mm in diameter and 12 mm in length cylinders used in dogs, sheep, or goats, and 2 to 4.5 mm in diameter if screw shaped in rabbits, dogs, sheep, goats or pigs.

Test and control have to be in contralateral locations.

A non-absorbable control at each timepoint

The femur or tibia are discussed as the implant sites.

The maximum sites for a rabbit are 3 test and 3 control.   The maximum sites for a dog, sheep, goat or a pig is 6 test and 6 control.

Implantation into brain

A non-absorbable control at each timepoint.

The size of an intraparenchymal rod or wedge shaped implant should be 1 mm in diameter or less and 2 to 6 mm in length.  But, a disk can be 8 mm in diameter.

Rats or rabbits.

Equal numbers of males and females.

8 test and 8 control, but not in the same animals, split equally amongst males and females.

Only use one side.  One site for rat and two for rabbits.

High resolution images are required.
Powered by Create your own unique website with customizable templates.
  • Home
  • Suppliers
    • Contract Laboratories >
      • Toxikon
      • Nelson Labs
      • Eurofins
    • Material Suppliers
    • Contract Manufacturers
    • Consultants >
      • Intrinsic Medical Group
  • Library
    • Which Endpoints Should I Consider?
    • Test Method Summaries
    • White Papers, Articles and Presentations >
      • FDA Guidance: Coronary, Peripheral, and Neurovascular Guidewires
      • FDA Recognized Consensus Standards Update
      • The Ten Steps of a Biological Evaluation whtin a Risk Management Process
      • Post-Approval Biocompatibility
      • The Failed Cytotoxicity Test
      • Biocompatibility Deficiency Letters Part 2
      • ISO 18562-1 (2017) Biocompatibility Evaluation of Breathing Gas Pathways
      • In-Vivo Thrombogenicity 101
      • Technical Considerations for Additive Manufactured (3D Printed) Devices
      • How to Pick a Biocompatibility CRO
      • Mitigating Risk in Biocompatibility
      • Biocompatibility Deficiency Letters
      • The First Steps in Biocompatibility
  • Contact
    • About
  • Search